Physician profile
Robert S Cooper
NPI 1548286396
$307.19
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $307.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $105.87 | 2019 | |
| Amgen INC. | $54.63 | 2019 | |
| Asd Specialty Healthcare, LLC | $38.05 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $17.71 | 2019 | |
| Genzyme Corporation | $16.75 | 2019 | |
| Eisai INC. | $15.79 | 2019 | |
| Genentech USA, INC. | $15.76 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $15.10 | 2019 | |
| Fortovia Therapeutics, INC. | $14.04 | 2019 | |
| Pfizer INC. | $13.49 | 2019 |
1 company reported research payments only; those appear in the research section below.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Cooper listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.